Cartesian Therapeutics (RNAC) Gross Profit: 2015-2025
Historic Gross Profit for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to $452,000.
- Cartesian Therapeutics' Gross Profit rose 16.80% to $452,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 97.72%. This contributed to the annual value of $38.9 million for FY2024, which is 49.64% up from last year.
- Latest data reveals that Cartesian Therapeutics reported Gross Profit of $452,000 as of Q3 2025, which was up 51.68% from $298,000 recorded in Q2 2025.
- Cartesian Therapeutics' Gross Profit's 5-year high stood at $39.3 million during Q2 2022, with a 5-year trough of -$759,000 in Q4 2024.
- Over the past 3 years, Cartesian Therapeutics' median Gross Profit value was $5.2 million (recorded in 2023), while the average stood at $6.1 million.
- In the last 5 years, Cartesian Therapeutics' Gross Profit skyrocketed by 9,691.71% in 2021 and then plummeted by 109.18% in 2024.
- Over the past 5 years, Cartesian Therapeutics' Gross Profit (Quarterly) stood at $29.9 million in 2021, then slumped by 43.90% to $16.8 million in 2022, then slumped by 50.78% to $8.3 million in 2023, then crashed by 109.18% to -$759,000 in 2024, then grew by 16.80% to $452,000 in 2025.
- Its Gross Profit stands at $452,000 for Q3 2025, versus $298,000 for Q2 2025 and $1.1 million for Q1 2025.